Doctors In DTC Ads Make A Difference, 20% Of Study Respondents Say
This article was originally published in The Pink Sheet Daily
Responding to Rodale's study, FDA's DDMAC says results show that marketers should identify whether doctors are real.
You may also be interested in...
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.